Ask any European private biotech company just a year ago on its plans for fundraising and a NASDAQ IPO would probably have figured highly in the answer. Since the start of 2022, though, new IPOs and secondary offerings have had a poor reception and back-door listings like SPAC transactions have been cancelled.
The bubble in the NASDAQ Biotech Index (NBI) that started in March 2020 with the hopes that the sector would resolve the pandemic continued to its bursting at the end...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?